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HDAC inhibitore through attachment to the complex glycolipid anchor glycosylphosphatidyl
inositol (GPI) is a mode of protein expression highly conserved in eukaryotes. The evolutionary purpose of
such an elaborate way of expressing proteins is not clear and neither is the functional role of GPI itself. GPI-
anchored proteins (GPI-AP) serve a variety of functions that include adhesion, receptors, signal transduction
and complement activation. GPI biosynthesis, a process that is accomplished in at least 9 steps and involves
several proteins, some with enzymatic activity, would be expected to be a fertile ground for development of
inherited, autosomal recessive disorders. However, until recently, paroxysmal nocturnal haemoglobinuria, a
rare haematological disorder caused by somatic mutations in the X-linked PIGA gene, was the only genetic
disorder affecting GPI biosynthesis. Here we review the clinical spectrum, biochemical defect and genetic
pathogenesis of inherited GPI deﬁciency, the ﬁrst described form of inherited, autosomal recessive disorder
of GPI biosynthesis and outline the molecular basis of targeted therapy for this condition.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Glycan modiﬁcation of secretory and surface proteins includes N-
linked glycosylation and O- and C-mannosylation [1–4]; attachment
to the glycosylphosphatidyl inositol (GPI) anchor and expression on
the cell surface as GPI-anchored proteins (GPI-AP) constitutes an
additional way of protein glycan modiﬁcation [5–8]. In this respect,
inherited disorders of the formation and function of GPI would
constitute a form of congenital disorder of glycosylation (CDG) [9]. In
this review, before elaborating on the clinical manifestations,
biochemical defects and molecular genetics and pathogenesis of the
GPI anchor deﬁciencies, a brief overview of its structure, biosynthesis
and function is given.2. Structure, biosynthesis and modiﬁcations of the GPI anchor
The GPI core backbone structure, EtNP-6Manα1-2Manα1-
6Manα1-4GlcNα1-6myoInositol-phospholipid (EtNP: ethanolamine
phosphate; Man: mannose; and GlcN: glucosamine), is conserved in
all eukaryotes, from parasites and fungi to mammals [5–8]. However,
several species- and tissue-speciﬁc differences in the modiﬁcation of
this core structure exist. Here we will discuss the structure,
modiﬁcations and the protein products required for the biosynthesis
of the mammalian GPI which takes place in at least 9 steps.+44 20 8742 9335.
radimitris).
ll rights reserved.2.1. Biosynthesis of mature GPI
GPI biosynthesis (recently reviewed in [6,7]) starts on the
cytoplasmic side of endoplasmic reticulum (ER) and involves the
transfer of GlcNAc from UDP-GlcNAc to PI (step 1). This reaction is
catalysed by a multi-subunit GPI-GlcNAc transferase (GPI-GnT)
comprising 6 proteins (PIG-A, PIG-C, PIG-H, PIG-P, PIG-Q, PIG-Y) all
of which appear essential for this step [6,7]. PIG-A provides the
catalytic function of GPI-GnT but the functions of the other ﬁve
subunits are not known. DPM2, a subunit of the Dol-P-Man synthase
required for mannosylation, also appears to co-operate with and
enhance the activity of GPI-GnT (see Fig. 1 for overview of the GPI
biosynthetic pathway).
In step 2, GlcNAc-PI is de-N-acetylated by the action of PIG-L, a
GlcNAc-de-N-acetylase generating thus GlcN-PI which in turn is
ﬂipped across to face the luminal side of ER (step 3) where the
synthesis of GPI continues [6,7]. The responsible ﬂippase remains
uncharacterised.
In step 4, by the action of the acyltransferase PIG-W, an acyl
chain is transferred from acyl-CoA to the inositol ring of PI to form
GlcN-(acyl)PI.
In the next 2 steps, Man residues are added sequentially to GlcN-
(acyl)PI generating Man-Man-GlcN-(acyl)PI. The PIG-M/PIG-X com-
plex is the GPI-MTI α1-4 mannosyltransferase required for the
addition of Man-1 (step 5) [6,7]. PIG-M is the catalytic subunit of
GPI-MTI while PIG-X, although devoid of catalytic activity, through its
stabilizing effect on PIG-M is essential for mannosylation. PIG-V is the
GPI-MTII α1-6 mannosyltransferase responsible for step 6, i.e.,
addition of Man-2 [6,7].
Fig.1. The biosynthetic pathway of GPI. GPI biosynthesis starts on the cytoplasmic face of ERwith the fatty acid chains of phosphatidylinositol embedded in the ER lipid bilayer. Step 1
is blocked in PNH as a result of mutations in PIGA. Through the action of a ﬂippase biosynthesis continues in the luminal side of ER. Step 5, i.e., addition of Man-1 is blocked in IGD due
to mutations in PIGM. Dol-P-Man, addition of Man-4, and lipid modiﬁcation of GPI are not shown.
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ETI), mediates EtNP modiﬁcation of Man-1 generating Man-(EtNP)
Man-GlcN-(acyl)PI [6,7].
Subsequently, in step 8, through the action of PIG-B, an α1-2
mannosyltransferase (GPI-MTIII), Man-3 is added to form Man-Man-
(EtNP)Man-GlcN-(acyl)PI [6,7].
In all 3 mannosylation steps, Dol-P-Man is the mannose donor
[6,7]. Synthesis of Dol-P-Man requires Dol-P-Man synthase, a 3
subunit complex consisting of DPM1, DPM2 and DPM3 [10]. DPM1 is
the catalytic subunit while DPM2 and 3 serve to stabilize DPM1.
In the ﬁnal step 9, through the action of GPI-ETIII, a complex of PIG-
O and PIG-F, the terminal EtNP which is crucial for protein attachment
to GPI is added to Man-3 generating thus the mature GPI structure
EtNP-Man-Man-(EtNP)Man-GlcN-(acyl)PI. Both PIG-F and PIG-O are
essential for the function of GPI-ETIII, with PIG-F required for the
stability of the complex and PIG-O providing the catalytic activity
[6,7].
In mammalian GPI another two modiﬁcations of the core EtNP-
Man-Man-(EtNP)Man-GlcN-(acyl)PI structure are possible. First, EtNP
modiﬁcation of Man-2 (step 10) by the action of PIG-G/PIG-F GPI-ETII
complex is often observed [6,7]. As for GPI-ETIII, PIG-G (GPI7) is the
catalytic sub-unit stabilized by PIG-F. A second possible modiﬁcation
taking place after step 8 and found mainly in the brain, is the addition
of a 4th mannose mediated by PIG-Z (SMP3), an α1-2 mannosyl-
transferase. The resulting intermediate containing four mannoses, is
then EtNP-modiﬁed at Man-3 (step 9′) generating thus another form
of mature GPI anchor [6,7].
2.2. Post-translational attachment of proteins to GPI
Attachment of a given protein to any of the 3 mature forms of GPI
described above has 2 structural requirements: the presence of an N-
terminus ER-targeting motif and of a C-terminus domain which
includes all the information required for attachment to GPI. The latter
involves the creation of an amidic bond between the so calledω aminoacid in the protein C-terminus and the EtNP attached to Man-3 [6,7].
This reaction (step 11) is mediated by the multi-subunit, membrane-
bound GPI transamidase comprising 5 proteins, all essential for the
function of the transamidase: PIG-K which provides the catalytic
activity, GAA1, PIG-S, PIG-T and PIG-U [6,7].
2.3. Post-protein attachment modiﬁcation of the GPI anchor
While still in the ER and after attachment of the protein to the GPI,
the acyl chain attached to the inositol moiety is removed by the action
of PGAP1, a deacylase [11]. Subsequent transport of GPI-AP to Golgi via
secretory vesicles requires a group of p24 family proteins [12,13].
While in the Golgi, fatty acid (FA) remodelling of PI takes place.
Speciﬁcally, the usually unsaturated FA at position sn2 of PI in GPI
precursors is converted, through the action of PGAP3, to lyso-GPI-AP
intermediate; subsequently, a saturated FA (usually stearic acid) is
added in a reaction requiring PGAP2 [14]. The presence of saturated FA
in both sn1 and sn2 positions of PI is thought to be required for stable
association of the GPI anchor with the outer leaﬂet of the cell
membrane and their incorporation into lipid rafts (see below) [14]. It
must be noted that, exceptionally, in human erythrocyte GPI-AP such
as CD59 neither the inositol ring acyl chain is removed nor the
unsaturated FA is replaced by saturated ones at position sn2 [6,15].
This ensures the presence of 3 FA chains stabilizing GPI-AP on the
surface of erythrocytes during their long life.
3. Biological signiﬁcance of the GPI anchor
Although GPI-AP serve a variety of functions (receptors, adhesion,
enzymes, complement regulation, signal transduction), the evolu-
tionary purpose of using a mechanism as elaborate as GPI linkage for
cell surface protein expression is not clear but its importance is
underscored by the fact that complete disruption of GPI biosynthesis
is embryonic lethal in mice [16,17] and conditional lethal in yeast
[18,19].
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the specialised membrane micro-domains called rafts, the relatively
rigid platforms on which through interaction of surface and
cytoplasmic proteins several signal transduction pathways are
triggered and vesicular trafﬁcking is organized [20–22]. Recent
evidence also suggests that GPI-linkage is required for many proteins
in order to assume their fully functional conformation [23]. GPI-
anchorage might also be important for apical targeting of proteins in
polarised cells such as those of the intestinal epithelium [24]. Another
potentially important function of GPI might be related to its
susceptibility to phospholipase C and D (PI-PLC and -PLD) cleavage
and release of the anchored protein. For example, Notum, a Wnt
pathway inhibitor possessing PI-PLC activity, can cleave and release
the GPI-anchored glypicans which in their soluble form may function
as inhibitors of Wnt interaction with its receptor [25]. Finally,
aerolysin, a pore-forming toxin from Aeromonas hydrophilia, requires
binding to surface GPI for its cell-killing activity [26].
4. Genetic disorders of GPI deﬁciency
The observation that complete disruption of GPI biosynthesis in
pig-a−/−mice results in embryonic lethality [16,17] whereas in vitro,
cells lacking expression of GPI as a result of various biosynthetic blocks
are not growth-restricted [27], would predict that GPI deﬁciency as a
genetic nosological entity could emerge either through acquired i.e.,
somatic mutations in certain tissues or cells (as in paroxysmal
nocturnal haemoglobinuria — PNH) or through inherited mutations
that allow reduced but sufﬁcient for survival synthesis of GPI (as in
inherited GPI deﬁciency — IGD).
5. Acquired GPI deﬁciency: PNH
Given the complexity and the large number of genes and their
protein products required for the biosynthesis of GPI, it was rather
surprising that until recently, the only human disorder associatedwith
GPI deﬁciency was PNH, a rare haematological disorder with dual
pathogenesis [28]. The ﬁrst pathogenetic requirement in PNH is a
somatic mutation affecting the X-linked PIGA gene in a single
haemopoietic stem cell (HSC) and its progeny, disrupting thus the
ﬁrst step in the GPI biosynthesis [29–31]. A second process, believed to
be a T-cell mediated autoimmune attack against normal but not GPI-
deﬁcient HSC, allows survival and expansion of the latter resulting in
the production of mature blood cells lacking synthesis of GPI and
expression of GPI-AP [28,32]. The clinical consequences are intravas-
cular haemolysis as a result of erythrocytes lacking expression of the
GPI-linked complement activation inhibitor CD59, propensity to
splanchnic and cerebral vein thromboses also possibly linked to
CD59 deﬁciency in erythrocytes and platelets, and ﬁnally bone
marrow failure and cytopenia as a result of the GPI+ HSC being the
targets of auto-aggressive T cells [33,34].
6. Inherited GPI deﬁciency
6.1. Clinical spectrum
Over a decade ago we studied two unrelated consanguineous
families (Family 1 of Middle Eastern and Family 2 of Turkish origin) in
which the index cases presented with abdominal vein thrombosis by
the age of two years [35]. Both children subsequently developed
persistent absence seizures. A younger sibling in Family 2 also
developed absence seizures but thrombosis was prevented because
prophylactic anticoagulation was instituted following pre-sympto-
matic diagnosis. Notably, none of the affected children exhibited
clinical evidence of signiﬁcant intravascular haemolysis or bone
marrow failure and cytopenia, and extensive imaging revealed no
evidence of cerebral venous thrombosis or other vascular abnormal-ities. The parents and unaffected siblings were asymptomatic. With
the exception of an intermittently low-positive Ham test suggesting
mild deﬁciency of the GPI-linked complement inhibitor CD59 [36],
acquired and inherited causes of thrombophilia were not found.
6.2. GPI surface expression in IGD
Staining with FLAER, an inactivated form of aerolysin and GPI-AP-
speciﬁc mAb showed that the expression pattern of GPI-linked
proteins and GPI itself on blood cells in IGD is distinct from that of
patients with PNH [35,37] (Fig. 2). The erythrocytes of the children
with IGD had near normal expression of CD59 with a small proportion
of cells (b5%) being completely deﬁcient. A similar patternwas seen in
platelets. This is different to the bi- or tri-modal pattern of CD59
expression in PNH representing populations with normal, complete or
intermediate loss of GPI biosynthesis respectively. By contrast,
expression of GPI on the surface of granulocytes in IGD was severely
reduced in a unimodal fashion while it is usually bi-modal in PNH.
Highlighting the cell- and tissue-dependent variability of its
severity, GPI deﬁciency in primary ﬁbroblasts from patients with
IGD was moderate rather complete.
6.3. Addition of Man-1 to the GlcN-(acyl)PI precursor is blocked in IGD
By the use of substrate labeling of patient-derived EBV-trans-
formed B cell lines, glycolipid extraction and high performance thin
layer chromatography the biochemical defect in IGD was pinpointed
in the addition of Man-1 to GlcN-(acyl)PI. As mentioned above, this
step is catalysed by the GPI-MTI comprising PIG-M, a multiple
membrane domain protein containing a luminal DXD motif char-
acteristic of many glycosyltransferases [38] and PIG-X.
6.4. PIG-M is the disease gene in IGD
In parallel genetic studies that included homozygosity mapping
using microsatellite markers ﬂanking almost all genes involved in GPI
biosynthesis, PIGMwas identiﬁed as one of the candidate genes in the
affected children of both families. PIGM was conﬁrmed as the disease
gene in IGD as its transfection into GPI- B cell lines from affected
children restored biosynthesis of GPI and expression of GPI-AP on the
cell surface.
6.5. IGD is caused by a hypomorphic promoter mutation
Screening for mutations in the single-exon PIGM revealed that
surprisingly the same CNG substitution at position−270 from ATG in
the promoter of PIG-M was present in both families and segregated
with the phenotype[35]. The same mutation was found in blood cells
and ﬁbroblasts in patients with IGD but it was not present in any of
control individuals from the patients' ethnic background.
Conforming to a typical recessive trait this promoter mutation
resulted in a drastically reduced PIGMmRNA in affected B-cell lines to
approximately 1% of normal and about half of normal in heterozygous
cell lines.
Bioinformatics analysis predicted that the−270CNG transversion
disrupted a GC-rich binding motif for the generic transcription factor
(TF) Sp1. It is notable that this GC-rich box is the most highly
conserved amongst all other predicted TF binding motifs in the
promoter of PIGM attesting thus to its functional importance. By a
combination of transactivation and electro-mobility shift assays these
predictions were conﬁrmed and it was found that the CNG transver-
sion severely reduced but not completely abrogated the transcrip-
tional activity of the PIGM promoter. This along the fact that in some
cells and tissues in patients with IGD expression of GPI was not
completely absent means that the −270CNG transversion is a
hypomorphic mutation whose impact on transcription varies from
Fig. 2. Expression of GPI in IGD and PNH. A. In patients with IGD, expression of the GPI-AP CD59 is near normal contrasting with the bi- or tri-modal pattern in PNH. Expression of
CD59 on erythrocytes from the parents of patients with IGD is normal. (FLAER is not suitable for erythrocyte staining). B. Expression of GPI and GPI-AP (CD59 and CD24) in
granulocytes. Note the unimodally severe deﬁciency of GPI expression in patients with IGD and the typically bimodal pattern in patients with PNH. The expression pattern in parents
of patients with IGD is identical to normal. C. Dot blot showing GPI and GPI-AP co-expression on ﬁbroblasts from a normal donor and a patient with IGD. Expression of GPI in IGD is
reduced but not completely deﬁcient.
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PIGM promoter requires a region of 2 kb upstream of ATG [35].
6.6. The transcription factor Sp1
Sp1 is a ubiquitously expressed transcription factor (TF) that
belongs to a wider family of Sp proteins, structurally characterised by
the presence of 3 carboxyterminal, DNA binding zinc ﬁnger (ZnF)
motifs [39–42].A large number of in vitro studies have shown that Sp1 can be
critical for efﬁcient transcription of many house-keeping and
inducible genes. Sp1 has been shown to enhance transcription
through a variety of mechanisms that include direct interactions
with elements of the TFIID complex of the basic transcriptional
complex [41,43], interactions with other TF such as GATA-1 [44–46],
and recruitment of histone modifying enzymes such as histone
acetyltransferases [47] and deacetylases [48] (HAT and HDAC
respectively). In addition, the function of Sp1 depends on its ability
878 A. Almeida et al. / Biochimica et Biophysica Acta 1792 (2009) 874–880to form tetramer homopolymers arranged in stacks and can be altered
by its covalent modiﬁcation, e.g., phosphorylation and acetylation
(reviewed in [40–42]).
All these interactions require binding of Sp1 through its ZnF motifs
to a GC-rich DNA element (motif) found in the proximal promoters of
all genes; GC-rich boxes are also found in distal promoters, enhancers
and locus control regions [40–42]. Sp3, another Sp TF binds to the
same motif with almost equal afﬁnity [40–42].
6.7. Sp1 and gene-speciﬁc histone hypoacetylation in IGD
One feature of the function of Sp1 that has attracted considerable
interest is its ability to control transcriptional activity through
recruitment to the promoter of histone modifying enzymes, especially
HAT and HDAC: in most cases the HAT activity prevails and favours
transcription.
Another interesting aspect of Sp1 and its binding element is their
role in mediating the effects of HDAC inhibition by butyrate and other
HDAC inhibitors. Although HDAC inhibition leads to widespread
increase in histone acetylation it only impacts on the transcription
rates of a minority (b5–10%) of genes [49–51]; and for a few amongst
these genes, enhanced transcription as a result of HDAC inhibition and
histone hyperacetylation, requires binding of Sp1 to its proximal
promoter elements (i.e., GC-rich box) [52–59]. However, it is not
known whether these butyrate responsive elements (BRE) are also
critical for the maintenance of histone acetylation during baseline
physiological transcription.
Using chromatin immunoprecipitation assays it was shown that in
the presence of the homozygous CNG mutation, histone 4 (H4) at the
native promoter of PIGM in patient B cell lines was hypoacetylated but
as it would be expected of a housekeeping gene, acetylated in the
parental B cell lines [37] implying that the Sp1 binding motif mutated
in IGD is important for maintenance of histone acetylation at the
promoter of PIGM and thus its transcriptional activity.
However, despite disruption of the critical proximal promoter GC-
rich motif, butyrate could still enhance activity of the mutated
promoter (although less so in comparison to the WT promoter)
suggesting the presence of additional BRE in the promoter of PIGM.
Although not adequate to sustain adequate baseline transcription,
these BRE could be required for the increased activity of the mutated
promoter after HDAC inhibition [37]. Software analysis indicated the
presence of another 3 GC-rich boxes upstream of the mutated motif
(Fig. 1), suggesting that Sp1 binding is required for the butyrate effect
on themutated promoter. This was conﬁrmed in reporter experiments
in which when binding of Sp1 to DNA was disrupted by mithramycin,
the butyrate-mediated enhancing effect was dramatically reduced for
the mutated as well as the WT promoter [37]. Furthermore, exposure
of the patients B cell lines to butyrate resulted in restoration of H4
acetylation in the native mutated PIGM promoter, a 20-fold increase of
the PIGMmRNA levels and complete restoration of GPI biosynthesis as
shown by normal expression levels of GPI-linked proteins on the cell
surface [37].
6.8. HDAC inhibition as a treatment for IGD
In view of these results we treated a child with IGD who suffered
chronic intractable seizures and severe disability with butyrate. This
resulted in the progressive increase of blood cell PIGM RNA levels from
∼1% to 60% and also a progressive increase in the expression of GPI-
linked molecules on the surface of granulocytes; more importantly,
2 weeks after commencement of butyrate, the child became seizure-
free for the ﬁrst time in 12 years [37].
Therefore, the PIGM mutation causing IGD results in signiﬁcant
perturbation of the epigenetic landscape in the promoter of PIGM and
eventually in a clinical phenotype directly-dependent on the
biosynthesis of GPI and cell surface expression of GPI-AP.7. A tentative model of transcriptional control of PIGM by Sp1 in
health and disease
Considering these ﬁndings we propose a model of transcriptional
control of PIGM by Sp1 (Fig. 3) whereby during baseline transcription
of PIGM, binding of Sp1 to the proximal promoter GC-rich box is
associated with co-recruitment of HAT and HDAC. Presumably in this
context, HAT prevails over HDAC activity ensuring histone acetylation
and normal transcriptional output. Similar arrangements might occur
in the upstream GC-rich boxes but their role may not be as signiﬁcant
in baseline transcription. In IGD, disruption of the proximal GC-rich
box by the CNG mutation signiﬁcantly reduces transcriptional output
in a cell- and tissue-dependent manner while Sp1 binding to
upstream GC-rich boxes is preserved. In the mutated promoter,
during butyrate treatment, selective HDAC inhibition leaves HAT
activity unopposed resulting in signiﬁcant restoration of histone
acetylation and thus of transcriptional activity and GPI biosynthesis.
8. IGD and other disorders of glycosylation
The topology of the assembly of GPI (i.e., ﬁrst on the cytoplasmic
and then lumenal side of the ER) hasmany similarities with that of the
N-glycan assembly; the two pathways also share 3 sugar donors,
namely GlcNac-UDP, Man-GDP and Dol-P-Man and possibly the same
ﬂippase [10]. Therefore, it would be expected that defects in the
synthesis of these 4 molecules would impact on both protein
glycosylation and GPI modiﬁcation. Thus far, only defects of Dol-P-
Man, the mannose donor required for N-glycan assembly, O- and C-
mannosylation of proteins as well as of GPI have been reported.
Speciﬁcally, in CDG1e, in which synthesis of Dol-P-Man is impaired as
a result of mutations in DPM1, reduced expression of GPI-AP in patient
ﬁbroblasts has been documented [60,61]. However, because the small
amount of Dol-P-Man synthesized in CDG1e is preferentially used in
the mannosylation of GPI [62,63] the observed deﬁciency is mild.
Instead, the shunting of Dol-P-Man away from the glycosylation
pathways leaves protein glycosylation severely disrupted. This leads to
the serious clinical phenotype of CDG1e (intractable seizures,
encephalopathy, microcephaly, dysmorphism but no thrombosis)
[60,61] which closely resembles that of other CDG disorders
[9,64,65] rather than IGD. In addition, because PIG-M catalyses the
α1-4 mannosylation of GlcN-(acyl)PI, a linkage not encountered in
other mannosylated lipids or proteins [9,65], selective GPI deﬁciency
is sufﬁcient to account for the phenotype in IGD.
9. IGD: questions and perspectives
9.1. A common ancestral mutation?
From the genetic viewpoint an interesting question is whether the
disruption of the same biosynthetic step involving the same gene and
identiﬁcation of exactly of the same mutation in ethnically different
families with IGD has occurred by chance or it reﬂects a mutation in a
common, distant ancestor. Arguing against the latter, microsatellite-
and SNP-based haplotypes encompassing PIG-M were clearly dis-
parate [35], suggesting that the mutation arose in the two families
independently and by chance.
9.2. Mechanism of cell- and tissue-dependent GPI expression variability
A second question pertains to the mechanism responsible for the
cell- and tissue-dependent variability in GPI synthesis in IGD as
exempliﬁed by the nearly normal expression of GPI in erythrocytes
and its severe deﬁciency in granulocytes. One possibility is that
transcription of PIGM might be regulated by erythroid-speciﬁc TF
which can maintain adequate transcriptional activity even in the
presence of themutated core promoter Sp1 bindingmotif. Preliminary
Fig. 3. A tentative model of transcriptional control of PIG-M by Sp1 in health and disease. A. Baseline transcriptional activity of the PIGM promoter depends on the RNA polymerase II
transcriptional machinery and the open conﬁguration of acetylated chromatin. Sp1 might regulate both processes by interacting with the Pol II complex and by ensuring histone
acetylation through its ability to recruit histone modifying enzymes, i.e., acetyl-transferases (HAT) and de-acetylases (HDAC). Under normal circumstances, the balance favours HAT
activity and thus acetylation of histones. B. In IGD, mutation in the core promoter Sp1 binding motif prevents Sp1 binding resulting in the interruption of its interactionwith the Pol II
complex and loss of its ability to recruit HAT/HDAC. The ensuing chromatin de-acetylation and condensation dramatically but not completely reduces transcriptional activity of the
PIGM promoter. C. In the presence of butyrate, a HDAC inhibitor, HDAC recruited to the upstream Sp1 binding motifs are inhibited leaving activity of HAT unopposed and thus
restoration of histone acetylation and transcriptional activity.
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[66] might play a critical role in this process (Almeida et al.,
unpublished data).
9.3. Mechanism of thrombosis and epilepsy
At the moment we can only speculate on the pathogenesis of
seizures and thrombosis in IGD and the role of speciﬁc GPI-AP in these
processes. The generation of a pigm cNg knock-in mouse model will
help greatly investigations towards this direction.
9.4. IGD caused by mutations in other genes of the GPI biosynthetic
pathways?
The paradigm of PIG-M-related IGD suggests that probably every
gene essential for GPI assembly suffering hypomorphic (e.g., promoter
or missense) mutations could lead to inherited deﬁciency of GPI.
However, this would be expected to be a very rare event occurring in
the context of consanguinity.
9.5. HDAC inhibition as a means to enhance transcription and activity of
house-keeping genes associated with human pathology
Because PIGM is a housekeeping gene and part of a ubiquitous
biosynthetic pathway it might be expected that other genes required
for GPI biosynthesis may be subject to the same type of Sp1-
dependent transcriptional control as PIGM. Extending this notion
further, it could be surmised that Sp1 and its control of histone
acetylation are also important for the transcription of genes that arepart of other house-keeping, enzyme-based pathways. If so, char-
acterisation of Sp1-binding motifs/BRE required for transcriptional
control of genes with these characteristics could offer new therapeutic
opportunities for inherited disorders of other ubiquitous metabolic
pathways such as glycolysis and in fact disorders of glycosylation.
Often in these autosomal recessive disorders, the molecular pathology
comprises missense mutations which allow for residual enzymatic
activity. Increased transcription and protein production induced by
HDAC inhibitors might translate to increased enzymatic activity and
thus amelioration of the cellular and clinical phenotype.Acknowledgements
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